businessbriefs
SubjectsAll subjects on briefs.cloud →
Saved
Companies · Product

Biogen

Cesar Milstein · 1978

Biogen didn’t emerge from Milstein’s lab — it emerged from strategic acquisitions, regulatory gambles, and the hard economics of neurological disease markets.

Worth your time?3.5/5Yes.Study the whole thing.What works, what does not, who it is for ↓
11:35in productionCh. 1 · What Biogen Is/ 11:35 · ceiling 15 min
6 chapters · 11:35Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.6 chapters · 1 min read · 11:35 planned

Read the brief

Biogen is a neurology-focused biotech that built scale via acquisition, not foundational science — and César Milstein, whose hybridoma work underpins modern antibody therapeutics, has no documented relationship to the company.

CompaniesProductMedicinePatentsDiseaseMedicine across the network →
Chapters & takeaways6
  1. 0:57
    What Biogen Is

    Biogen is a U.S.-based biotech firm founded in 1978, focused exclusively on neurological diseases.

  2. 2:20
    Where the Money Comes From

    Over two-thirds of Biogen’s 2024 revenue came from six neurological drugs — none derived from monoclonal antibodies.

  3. 4:01
    How It Grew

    Biogen grew through targeted acquisitions — not internal discovery — buying Fumapharm, Conforma, and Syntonix in rapid succession.

  4. 5:26
    What Went Wrong

    Tysabri’s association with PML in 2008 exposed the clinical and reputational cost of fast-tracking high-efficacy neurotherapies.

  5. 6:53
    Milstein Had Nothing to Do With Biogen

    Milstein co-developed the hybridoma technique in 1975 and patented monoclonal antibody production — but had no connection to Biogen.

  6. 8:01
    The Field vs. The Firm

    Milstein’s work enabled the broader biotech industry — but Biogen’s own pipeline bypassed monoclonal antibodies entirely.

3 more chaptersFewer chapters
Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • clinical asset acquisition
  • neurology market concentration
  • post-approval risk management
What does not
  • César Milstein founded Biogen
  • Biogen developed monoclonal antibodies
  • Biogen’s pipeline stems from hybridoma technology
Study it if
  • biotech strategists
  • regulatory analysts
  • pharma historians
Skip it if
  • antibody researchers
  • Milstein biographers
  • startup founders seeking origin myths
Who should study it, and who should skipHide who it is for
The written brief1 min read

What the company or idea is

Biogen is a U.S.-based multinational biotechnology company founded in 1978 and headquartered in Cambridge, Massachusetts, specialising in neurological disease treatment.

How it actually makes money

Biogen makes money by commercialising neurological disease treatments — primarily MS drugs like Tecfidera and AVONEX, SMA drug Spinraza, and newer therapies like Qalsody and Skyclarys — with these products accounting for over two-thirds of 2024 revenues.

What works

Acquisitions like Fumapharm AG and Syntonix Pharmaceuticals delivered pipeline assets (Fumaderm, BG-12, hemophilia B drug) and platform tech (inhalable delivery); licensing and spin-offs (Bioverativ) extracted value from non-core assets.

What does not

Biogen does not own or operate the hybridoma technique. César Milstein developed it in 1975; he did not found Biogen, nor is there any link between him and the company in the source material.

What to take from it

The gap between Biogen’s origin story and its actual scientific lineage matters: it built its business on fumarates and interferons, not monoclonal antibodies — despite the field Milstein helped create enabling much of modern biotech.

Is it worth your time

Yes — but only if you are studying how biotech firms pivot from antibody science to neurology, manage clinical risk (e.g., PML), and monetise legacy assets while navigating regulatory reversals like Aducanumab’s abandonment.

Same desk · Companies4 of 325
9:28
Regeneron PharmaceuticalsGeorge Yancopoulos · 1988Regeneron is a biotech firm whose core innovation — the receptor trap — emerged from neurobiology, not pharmacology. It monetises that science via high-value partnerships and outsized government contracts, not broad platform dominance. Its success depends less on internal scale than on strategic leverage of public R&D funding.
11:25
DTE Energy1995DTE Energy is a Michigan-centric utility with a fossil-heavy generation profile and an opaque non-utility expansion. Its business model relies on regulatory protection, not market innovation.
9:48
Eisai (company)1936Eisai built its US presence not through independent scale but through three calibrated moves: co-marketing approvals with giants, buying discrete oncology assets, then spending $3.9 billion to acquire infrastructure. Its story is one of deliberate, capital-intensive delegation — not disruption, not invention, not integration.
10:39
Oracle CorporationLarry Ellison · 1977Oracle Corporation is a multinational technology company founded in 1977 in Santa Clara, California, by Larry Ellison, Bob Miner, and Ed Oates. It sells database software (especially Oracle Database), enterprise applications (ERP, HCM, CX, SCM), and cloud infrastructure and hardware. By the mid-2000s, it had become the world's largest enterprise software vendor. Its foundational database design drew from Edgar F. Codd’s relational model paper. IBM’s delay in releasing a relational database for Unix and Windows allowed Oracle to dominate mid-range and microcomputer systems. Oracle acquired Sun Microsystems in 2010 after regulatory approval in the U.S. and EU.
Up next in Business

Blackstone Inc.

Stephen Schwarzman · 1985 · 10:42

Blackstone didn’t build a firm — it built a permission structure for capital.

Next brief →Back to Companies
10:42